Strategic partnerships Prospective collaboration opportunities with large pharma and biotech players using Proteros’ integrated discovery platform to accelerate target-to-lead timelines, leveraging current partner traction with Orion and Adrestia to expand co-development deals.

Expanded target versatility Capitalize on Proteros’ ability to tackle challenging targets using structural biology, X-ray crystallography, Cryo-EM, and computational chemistry to pitch services for hard-to-drug targets across diverse therapeutic areas, appealing to companies seeking first-in-class candidates.

End-to-end discovery Highlight the seamless platform that combines protein sciences, screening, and medicinal chemistry to offer faster timelines and reduced risk, targeting firms aiming to shorten discovery phases and improve project velocity.

Platform synergies Leverage existing tech stack and cloud capabilities (AWS, Azure) to propose scalable collaboration models, data-driven decision making, and joint digital experimentation programs with potential partners seeking robust analytics and traceability.

Growth signals With multiple collaborations and a revenue range of 10-25 million USD and ongoing fundraising, emphasize Proteros’ growth trajectory and stability to secure larger strategic partnerships and multi-program engagements.